Abstract 6024: A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors

癌症研究 医学 化学
作者
Yoshihide Mizukoshi,Shota Tsuchida,Hiroko Inaba,Tatsuro Kotake,Takanori Aoki,Kai Orihara,Yuichi Funase,Naoki Kanazawa,Hikaru Shimizu,Kaita Sawano,Kentaro Suzuki,Hayato Yanagida,Takeru Ehara,Hidetomo Kitamura,Satoshi Matsushima,Masato Murakami
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 6024-6024
标识
DOI:10.1158/1538-7445.am2024-6024
摘要

Abstract Introduction: Carbonic Anhydrase IX (CA9) is a zinc metalloenzyme that regulates the pH for cell growth. CA9 is considered an attractive target and is upregulated in a variety of cancers, especially, in 95% of clear cell renal cell carcinoma (ccRCC) where there remains a large clinical unmet need despite the availability of several newly approved medicines. PeptiDream has identified PD-32766, a novel macrocyclic peptide, targeting CA9 and can be labeled with radionuclides such as copper (64Cu) and lutetium (177Lu), which enables tumor-specific PET bioimaging and radiotherapy. Here we report the theranostic translational feasibility of PD-32766 for ccRCC. Materials and Methods: PD-32766 was discovered using Peptide Discovery Platform System (PDPS), a proprietary screening system of PeptiDream. Binding affinity of PD-32766, 63Cu-PD-32766 and 175Lu-PD-32766 to CA9 was measured by SPR. For in vivo evaluation, we used a xenograft model in which VMRC-RCW (ccRCC cell line with similar CA9 expression level to clinical samples) was subcutaneously transplanted into nude mice. To assess biodistribution, 64Cu-PD-32766 or 177Lu-PD-32766 was dosed to VMRC-RCW xenograft mice, and the percentage of injected dose in tumors and major organs was quantified by cut and count method. To evaluate whether PET imaging can detect tumors, 64Cu-PD-32766 was dosed to VMRC-RCW xenograft mice and after dosing, PET scanning was performed. For therapeutic experiments, 177Lu-PD-32766 was dosed to VMRC-RCW xenograft mice and tumor volume was measured for 45 days after dosing. Results: SPR analysis revealed that PD-32766, 63Cu-PD-32766 and 175Lu-PD-32766 exhibits an affinity of less than 0.2 nM for CA9. In in vivo biodistribution experiment, 64Cu-PD-32766 and 177Lu-PD-32766 showed specific and strong accumulation in tumors 4 hours after dosing (88 and 107% ID/g, for 64Cu-PD-32766 and 177Lu-PD-32766, respectively) and were highly retained in the tumors at 48 hours after dosing (37 and 51% ID/g, for 64Cu-PD-32766 and 177Lu-PD-32766, respectively). Maximal intensity in other normal tissues were 23 and 9 %ID/g (tumor/kidney=3.8 and 11.9 for 64Cu-PD-32766 and 177Lu-PD-32766, respectively at 4 hrs.). PET bioimaging of 64Cu-PD-32766 clearly detected only tumors, consistent with the biodistribution data. In therapeutic experiments, 177Lu-PD-32766 (30 MBq/mouse single or QW x3) was well tolerated and strikingly improved mouse survival compared with control animals for 45 days after transplantation, which suggests a robust tumor growth inhibition of 177Lu-PD-32766 dosing. Taken together, PD-32766 showed specific tumor accumulation and strong therapeutic effect in a clinically relevant xenograft model of ccRCC. Conclusion: PD-32766 has preferable properties for imaging and therapy with radionuclides and a great potential for theranostic use in ccRCC. Citation Format: Yoshihide Mizukoshi, Shota Tsuchida, Hiroko Inaba, Tatsuro Kotake, Takanori Aoki, Kai Orihara, Yuichi Funase, Naoki Kanazawa, Hikaru Shimizu, Kaita Sawano, Kentaro Suzuki, Hayato Yanagida, Takeru Ehara, Hidetomo Kitamura, Satoshi Matsushima, Masato Murakami. A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6024.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
4秒前
Ning完成签到,获得积分10
7秒前
图图完成签到,获得积分10
7秒前
勤奋的灯完成签到 ,获得积分10
7秒前
ludong_0完成签到,获得积分10
7秒前
Asumita完成签到,获得积分10
8秒前
双青豆完成签到 ,获得积分10
8秒前
10秒前
fxy完成签到 ,获得积分10
11秒前
合适的幻然完成签到,获得积分10
11秒前
沐雨汐完成签到,获得积分10
13秒前
15秒前
16秒前
jiayoujijin完成签到 ,获得积分10
16秒前
淡然思卉完成签到,获得积分10
17秒前
争当科研巨匠完成签到,获得积分10
17秒前
英姑应助认真的刺猬采纳,获得10
24秒前
好大一只小坏蛋完成签到,获得积分20
24秒前
站走跑完成签到 ,获得积分10
27秒前
步步高完成签到,获得积分10
29秒前
无私的雪瑶完成签到 ,获得积分10
29秒前
小杨完成签到,获得积分20
30秒前
小花完成签到 ,获得积分10
35秒前
宁夕完成签到 ,获得积分10
39秒前
西宁完成签到,获得积分10
39秒前
拼搏的羊青完成签到 ,获得积分10
40秒前
科目三应助asd113采纳,获得10
40秒前
deng203完成签到 ,获得积分20
42秒前
43秒前
时米米米完成签到,获得积分10
43秒前
浅浅完成签到,获得积分10
47秒前
量子星尘发布了新的文献求助10
52秒前
帅气的藏鸟完成签到,获得积分10
56秒前
加油完成签到 ,获得积分10
57秒前
健康的宛菡完成签到 ,获得积分10
58秒前
橙果果发布了新的文献求助20
58秒前
晚晚完成签到,获得积分10
59秒前
59秒前
听闻韬声依旧完成签到 ,获得积分10
59秒前
ZHZ完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022